The Nasdaq site now discloses the following information on the FMR holding in Insmed -
Shares added during Q4 - 2,818,614
Shares held at the end of Q4 - 4,700,614
This exposes several lies posted by Terry mid-November under various ids in response to the information that FMR had purchased about two million shares, such as -
"Reply to What prompted FMR to buy two million shares recently?
terry_insm Nov 18, 2012 10:35 AM
Jay Venkatesan did. (Ayer) 3.1"
If Terry had the intelligence to understand SEC filings perhaps he wouldn't have lost so much money over the years. But that Nasdaq information leaves him nowhere to run.
For the serious investors here it's worth taking a step back in order to see the bigger picture. The information shown above suggests an FMR holding at the start of Q4 of 1,881,752 shares (the Beacon Bioventures holding).
The latest SEC filing reports a CURRENT holding of 2,818,594 shares - very close to the number of shares reported as acquired during Q4.
It seems as though FMR has replaced its 1,881,752 Beacon Bioventures holding with a 2,818,594 holding in subsidiaries which invest in established companies rather than start-ups.
Backwardpalm - you know Terry better than anybody else who uses this forum. Can you shed any light on why somebody with his experience doesn't understand SEC filings which a few shareholders who use this forum understand perfectly well?
Do you remember Terry also disputing the number of shares bought by the Directors immediately after Insmed announced last year that it was "postponing" its planned US CF Phase III clinical trial?
We can all see now why they might have been worried about accusations of insider trading (presumably they realised they probably wouldn't need to run the study at all). But as to the share buying itself - why do you think somebody of Terry's experience is unable to read a Form 4?